IDEMIA
19.7.2021 11:28:07 CEST | Business Wire | Press release
IDEMIA Group announced today the appointment of Dominique Cerutti as Group Board Member, effective July 1st 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005297/en/
Dominique Cerutti comes with over 35 years of experience in Technology, R&D and Engineering services. He has held several CEO positions of leading technology companies and his expertise in growing large-scale international businesses will be a significant contribution to IDEMIA’s strategic vision.
“Dominique is a very seasoned leader with a demonstrated track record in transforming and growing large-scale international technology businesses. He will be instrumental for the Group moving forward”, said Pierre Barrial, IDEMIA Group President & CEO.
“We are pleased to welcome Dominique Cerutti to the IDEMIA Board. With more than 35 years of experience, Dominique is an undisputed expert in security and technology and a tremendous addition to IDEMIA’s Board” said Yann Delabrière, Chairman of the Board
“I couldn’t be more honored and thrilled to be joining IDEMIA, global leader in Augmented Identity, at an exciting time in its development. I look forward to offering strategic guidance and contributing to making the world a safer place”, said Dominique Cerutti.
NOTE TO EDITORS – Dominique Cerutti’s biography
Starting June 2015, Dominique Cerutti spent 5 years as Chief Executive Officer of the Altran group. He was also Chairman of the Altran Board from June 2015 to April 2020, until the acquisition of the company by Capgemini. Under his leadership, Altran has become the undisputed global leader in Engineering and R&D services, growing from 20,000 to more than 50,000 engineers worldwide, with revenues up to 3.2bn euros. He has deeply transformed the company by adapting the organization, promoting new business models and driving major acquisitions, enabling Altran to stay ahead of the competition, drive the market and reshape the global ER&D industry. Fervent advocate of the acquisition by Capgemini, he has worked hand in hand with the Group to make the integration a success and stepped down at the end of 2020.
Before joining Altran, Dominique Cerutti was CEO and Chairman of the Managing Board of Euronext, the leading pan-European exchange. He established Euronext as an independent company and the leading pan-European Exchange, through a successful IPO following the acquisition of NYSE-Euronext by the ICE Group in November 2013 and the subsequent demerger of Euronext from NYSE. He led the strategic repositioning of Euronext as the premier pan-European financing center. He and his team have been deeply involved with the correction of the previously biased EU financial markets regulation, promoting transparency and increased investors protections within the EU financial markets.
He was previously President and Deputy CEO, and a board member of New-York Stock Exchange (NYSE), the world’s leading exchange Group.
Dominique Cerutti also spent over 20 years at IBM in an international career, where he contributed to the company’s strategic transformation. In particular, he served as Chief Executive Officer of IBM Global Services for the Europe, Middle East, Africa, and later for IBM Europe, after being Executive Assistant to Lou Gerstner, Chairman and CEO of IBM.
He held various Board positions at LCH-Clearnet, Euromed Business School, New-York Stock Exchange, Altran, Euronext, Genes’ink.
Since March 2021, he is chairman of Adarma’s Board, one of the largest independent security services companies in the UK.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom